Tumour Infiltrating Lymphocyte Therapy Market Size
Tumor-Infiltrating lymphocyte (TIL) therapy market size was valued at USD 0.1 Billion in 2024 and is expected to reach USD 2.1 Billion by 2034, growing at a CAGR of 40%
TIL therapy is the newest variety of adoptive cell transfer immunotherapy for treating cancer. The idea of this kind of personalized treatment lies in using a patient's immune cells to fight cancerous cells. A simple explanation of it can be that, for the treatment, T lymphocytes will be taken out from a tumor after which they are multiplied. These were some of the white blood cells of a patient's system that had crossed the tumor but lost their ability to fight. It all starts with the surgical removal of part of a patient's tumor. Scientists then isolate the TILs from the sample, after which they are cultured and expanded in a laboratory. Such expansion takes several weeks—billions of TILs. In the meantime, the patient usually undergoes a lymphodepleting chemotherapy regimen to make space in the immune system for the new TILs. After sufficient expansion of the TILs, they are reinjected into the patient's bloodstream. Now, these reinfused TILs are geared to recognize and attack the cancer cells specifically. This is followed by the usual administration of high doses of interleukin-2, a protein stimulating the growth and activity of T cells, after the infusion to further enhance the therapy's effectiveness.